Kathryn R Tringale1, Dana L Casey2, Gregory Niyazov3, Jessica A Lavery4, Chaya Moskowitz4, Danielle N Friedman5, Suzanne L Wolden1. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2. Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina, USA. 3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 5. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abstract
BACKGROUND: It is unclear how intensity-modulated radiation therapy (IMRT) impacts long-term risk of second malignant neoplasms (SMNs) in childhood cancer patients. PROCEDURE: Patients aged ≤21 years treated with IMRT between 1998 and 2009 and who survived ≥5 years after IMRT were included. SMN site in relation to isodose level (IDL) of IMRT was evaluated. Standardized incidence ratios (SIR) and excess absolute risks (EAR) were calculated. Cumulative incidences were estimated with death as a competing risk. RESULTS: Three-hundred twenty-five patients were included with median follow-up of 11.2 years from IMRT (interquartile range: 9.4-14.0) among patients alive at the end of follow-up. Two hundred (62%) patients had ≥10 years of follow-up and 284 (87%) patients were alive at the time of analysis. Fifteen patients developed SMNs (11 solid, four hematologic). Median time from IMRT to solid SMN was 11.0 years (range: 6.8-19.2) with 10- and 15-year cumulative incidences 1.8% (95% CI: 0.7-3.9) and 3.5% (95% CI: 1.4-7.5), respectively; SIR was 13.7 (95% CI: 6.9-24.6) and EAR was 2.8 per 1000 person-years (95% CI: 1.0-4.6). Eight solid SMNs developed within the IMRT field (100% IDL [n = 5], 80% IDL [n = 1], 50% IDL [n = 1], 40% IDL [n = 1]), one within the 70%-80% IDL of a conventional field, one was out-of-field, and one could not be determined. CONCLUSIONS: With median follow-up of >10 years, many solid SMNs after IMRT in childhood cancer survivors develop in the high-dose region. These data serve as a foundation for comparison with other modalities of radiation treatment (e.g., proton therapy).
BACKGROUND: It is unclear how intensity-modulated radiation therapy (IMRT) impacts long-term risk of second malignant neoplasms (SMNs) in childhood cancer patients. PROCEDURE: Patients aged ≤21 years treated with IMRT between 1998 and 2009 and who survived ≥5 years after IMRT were included. SMN site in relation to isodose level (IDL) of IMRT was evaluated. Standardized incidence ratios (SIR) and excess absolute risks (EAR) were calculated. Cumulative incidences were estimated with death as a competing risk. RESULTS: Three-hundred twenty-five patients were included with median follow-up of 11.2 years from IMRT (interquartile range: 9.4-14.0) among patients alive at the end of follow-up. Two hundred (62%) patients had ≥10 years of follow-up and 284 (87%) patients were alive at the time of analysis. Fifteen patients developed SMNs (11 solid, four hematologic). Median time from IMRT to solid SMN was 11.0 years (range: 6.8-19.2) with 10- and 15-year cumulative incidences 1.8% (95% CI: 0.7-3.9) and 3.5% (95% CI: 1.4-7.5), respectively; SIR was 13.7 (95% CI: 6.9-24.6) and EAR was 2.8 per 1000 person-years (95% CI: 1.0-4.6). Eight solid SMNs developed within the IMRT field (100% IDL [n = 5], 80% IDL [n = 1], 50% IDL [n = 1], 40% IDL [n = 1]), one within the 70%-80% IDL of a conventional field, one was out-of-field, and one could not be determined. CONCLUSIONS: With median follow-up of >10 years, many solid SMNs after IMRT in childhood cancer survivors develop in the high-dose region. These data serve as a foundation for comparison with other modalities of radiation treatment (e.g., proton therapy).
Authors: Stephen F Kry; Mohammad Salehpour; David S Followill; Marilyn Stovall; Deborah A Kuban; R Allen White; Isaac I Rosen Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-15 Impact factor: 7.038
Authors: M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel Journal: Radiother Oncol Date: 2000-06 Impact factor: 6.280
Authors: Maureen M O'Brien; Sarah S Donaldson; Raymond R Balise; Alice S Whittemore; Michael P Link Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Lene H S Veiga; Erik Holmberg; Harald Anderson; Linda Pottern; Siegal Sadetzki; M Jacob Adams; Ritsu Sakata; Arthur B Schneider; Peter Inskip; Parveen Bhatti; Robert Johansson; Gila Neta; Roy Shore; Florent de Vathaire; Lena Damber; Ruth Kleinerman; Michael M Hawkins; Margaret Tucker; Marie Lundell; Jay H Lubin Journal: Radiat Res Date: 2016-04-29 Impact factor: 2.841
Authors: Kristy R Kutanzi; Annie Lumen; Igor Koturbash; Isabelle R Miousse Journal: Int J Environ Res Public Health Date: 2016-10-28 Impact factor: 3.390
Authors: A Kuendgen; M Nomdedeu; H Tuechler; G Garcia-Manero; R S Komrokji; M A Sekeres; M G Della Porta; M Cazzola; A E DeZern; G J Roboz; D P Steensma; A A Van de Loosdrecht; R F Schlenk; J Grau; X Calvo; S Blum; A Pereira; P Valent; D Costa; A Giagounidis; B Xicoy; H Döhner; U Platzbecker; C Pedro; M Lübbert; I Oiartzabal; M Díez-Campelo; M T Cedena; S Machherndl-Spandl; M López-Pavía; C D Baldus; M Martinez-de-Sola; R Stauder; B Merchan; A List; C Ganster; T Schroeder; M T Voso; M Pfeilstöcker; H Sill; B Hildebrandt; J Esteve; B Nomdedeu; F Cobo; R Haas; F Sole; U Germing; P L Greenberg; D Haase; G Sanz Journal: Leukemia Date: 2020-06-29 Impact factor: 11.528
Authors: Daniel J Indelicato; James E Bates; Raymond B Mailhot Vega; Ronny L Rotondo; Bradford S Hoppe; Christopher G Morris; Wen S Looi; Eric S Sandler; Philipp R Aldana; Julie A Bradley Journal: Pediatr Blood Cancer Date: 2021-02-09 Impact factor: 3.167